α-D-Gal-cyclophellitol cyclosulfamidate is a Michaelis complex analog that stabilizes therapeutic lysosomal α-galactosidase A in Fabry disease by Artola, Marta et al.
This is a repository copy of α-D-Gal-cyclophellitol cyclosulfamidate is a Michaelis complex 
analog that stabilizes therapeutic lysosomal α-galactosidase A in Fabry disease.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/149992/
Version: Accepted Version
Article:
Artola, Marta, Hedberg, Christinne, Rowland, Rhianna J. et al. (11 more authors) (2019) 
α-D-Gal-cyclophellitol cyclosulfamidate is a Michaelis complex analog that stabilizes 
therapeutic lysosomal α-galactosidase A in Fabry disease. Chemical Science. ISSN 
2041-6539 
https://doi.org/10.1039/C9SC03342D
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
  
Chemical Science 
ARTICLE 
  
Please do not adjust margins 
Please do not adjust margins 
Received 00th January 20xx, 
Accepted 00th January 20xx 
DOI: 10.1039/x0xx00000x 
 
α-D-Gal-cyclophellitol cyclosulfamidate is a Michaelis complex 
analog that stabilizes therapeutic lysosomal α-galactosidase A in 
Fabry disease 
Marta Artolaa,b, Christinne Hedberga, Rhianna J. Rowlandc, Lluís Raichd, Kassiani Kytidoub, Liang Wuc, 
Amanda Schaafa, Maria Joao Ferrazb, Gijsbert A. van der Marela, Jeroen D. C. Codéea, Carme 
Rovirad,e, Johannes M. F. G. Aertsb, Gideon J. Daviesc,*, Herman S. Overkleefta,* 
Fabry disease is an inherited lysosomal storage disorder that is characterized by a deficiency in lysosomal α-D-galactosidase 
activity. One current therapeutic strategy involves enzyme replacement therapy, in which patients are treated with 
recombinant enzyme. Co-treatment with enzyme active-site stabilizers is advocated to increase treatment efficacy; a 
strategy that requires effective and selective enzyme stabilizers. Here, we describe the design and development of an α-D-
gal-cyclophellitol cyclosulfamidate as a new class of neutral, conformationally-constrained competitive glycosidase inhibitor 
that acts by mimicry of the Michaelis complex conformation. We found that D-galactose-configured α-cyclosulfamidate 4 
effectively stabilizes recombinant human α-D-galactosidase (agalsidase beta, Fabrazyme®) both in vitro and in cellulo.
Introduction 
Deficiency in α-galactosidase A (α-gal A, EC 3.2.1.22, a retaining 
glycosidase of the GH27 glycoside hydrolase family 
(www.cazy.org)1) underlies Fabry disease. This inherited 
lysosomal storage disorder is characterized by toxic 
accumulation of glycosphingolipid globotriaosylceramide (Gb3) 
in lysosomes and its sphingoid base, globotriaosylsphingosine 
(Lyso-Gb3) in plasma and tissues2,3. Several mutations in the 
GLA gene encoding α-gal A can result in diminished protein 
levels and/or enzyme activity, leading to altered metabolite 
levels and a range of Fabry disease phenotypes. The 
accumulation of glycosphingolipid metabolites is thought to 
cause progressive renal and cardiac insufficiency and CNS 
pathology in Fabry patients4. Enzyme replacement therapy 
(ERT) for Fabry disease involves intravenous treatment with 
recombinant human α-gal A (agalsidase beta, Fabrazyme® or 
agalsidase alpha, Replagal®), but the clinical efficacy of this 
therapy is limited5–7. 1-Deoxygalactonojirimycin (Gal-DNJ 8, 
Migalastat®, Figure 1B) has recently been approved as 
pharmacological chaperone (PC) for the treatment of Fabry 
disease in patients with amenable mutations8. Gal-DNJ 8 binds 
mutant forms of α-gal A, which are catalytically competent but 
otherwise targeted for degradation due to misfolding. Gal-DNJ 
8 stabilizes the protein fold, allowing the mutant α-gal A to be 
trafficked to lysosomes. However, PC therapy for Fabry disease 
is limited to specific mutations and its efficacy is hotly debated9–
13. For this reason, an attractive alternative therapeutic 
intervention strategy, proposed recently, comprises jointly-
administering recombinant enzyme and a pharmacological 
chaperone14–16. This strategy aims to stabilize the recombinant 
enzyme in circulation such that larger proportions may reach 
disease affected tissues; permitting the use of extended 
intervals between injections and lower enzyme dosages which 
should diminish side effects, improve patient’s life-style and 
reduce treatment costs17,18. For this strategy to become clinical 
practice, allosteric enzyme stabilizers or orthosteric competitive 
α-gal A inhibitors that prevent enzyme unfolding and are 
displaced by the accumulated metabolites in the lysosome 
recovering the glycosidase activity, with good selectivity and 
pharmacokinetic/ pharmacodynamic properties, are 
required16,18,19. We argue that the discovery of such 
commodities would be greatly facilitated by the design of new 
inhibitor templates. 
Human α-gal A hydrolyzes its substrate following a Koshland 
double displacement mechanism, resulting in net retention of 
stereochemistry at the anomeric center of the produced 
galactopyranose20,21. The reaction coordinates by which α-gal A 
processes its substrate to form the intermediate covalent 
adduct are 4C1 → 4H3⧧ → 1S3 with respect to the conformation 
of the galactopyranose moiety in the Michaelis complex → TS 
→ covalent intermediate complex (Figure 1A)22–24. This same  
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Figure 1. Reaction coordinates of α-galactosidases and inhibitors. A. Reaction itinerary of retaining α-galactosidase, showing conformations of the 
Michaelis complex, transition state, and covalent intermediate. B. Chemical structures of α-glucose configured cyclosulfate 1, α-galactose 
configured cyclosulfate 2, cyclosulfamidates 3 and 4, cyclosulfamide 5, cyclophellitol 6, cyclophellitol aziridine 7, 1-deoxygalactonojirimycin 8 and 
β-galactose configured cyclosulfate 9. Galactose configured cyclosulfate 2 and cyclosulfamidate 4 inhibit α-galactosidases irreversibly (C) or 
reversibly (D) by mimicking the 4C1 “Michaelis-like” conformation. 
 
reaction itinerary is also employed by GH31 retaining α-
glucosidases, with the difference that a glucopyranose, rather 
than a galactopyranose, is captured in the enzyme active site25. 
We have recently shown that α-glc-cyclosulfate 1 (Figure 1B) 
potently, selectively and irreversibly inhibits retaining α-
glucosidases. Compound 1 in free solution predominantly 
resides in a 4C1 chair conformation, thus mimicking the initial 
Michaelis complex conformation utilized by α-glucosidases25 
allowing facile interception by the catalytic nucleophile.  
We reasoned that α-gal-cyclosulfate 2 would covalently and 
irreversibly inhibit α-gal A with equal efficiency and selectivity 
following the same mode of action (Figure 1B and 1C). Building 
on this concept, we further hypothesized that substitution of 
one or both of the cyclosulfate ring oxygens for nitrogen, as in 
compounds 3-5, would lead to competitive α-gal A inhibitors 
because of the decreased leaving group capacity of 
cyclosulfamidates/cyclosulfamides, when compared to 
cyclosulfates (Figure 1D). Such compounds would then offer 
competitive enzyme inhibitors to be tested as stabilizers of 
recombinant α-galactosidase A for Fabry treatment. Here, we 
show the validity of this reasoning by revealing α-gal-
cyclosulfamidate 4 as a first-in-class, effective and selective, 
competitive α-gal A inhibitor. Structural and computational 
analysis of the conformational behavior of compound 4 in 
solution and in the active site of human α-gal A supports our 
design and provides a molecular rationale why compound 4 is 
an effective α-gal A inhibitor. We also show compound 4 to be 
effective in stabilizing recombinant α-gal A in vitro and in cellulo 
and that sphingolipid levels in Fabry fibroblasts are effectively 
corrected by co-treatment with α-gal A and 4. 
Results 
Synthesis of α-D-galactose configured cyclosulfate 2 and 
cyclosulfamidate 4. 
Benzoylated diol 11 (see SI and Scheme S1 for its synthesis) was 
treated with thionyl chloride and subsequently oxidized with 
ruthenium trichloride and sodium periodate to afford protected 
cyclosulfate 12. α-Gal-cyclosulfate 2 was obtained after benzoyl 
removal using methanolic ammonia (Scheme 1A). The synthesis 
of cis-1-amino-6-hydroxy cyclohexane 18, a key intermediate in 
the synthesis of α-gal-cyclosulfamidate 4 proceeded through 
oxazolidinone 17, which was obtained from trans-azido alcohol 
13 (itself obtained from perbenzylated galacto-cyclophellitol, 
see the SI) as depicted in Scheme 1B. Hydrolysis of the 
carbamate in 17 and N-Bocylation provided 19, which was 
transformed into fully protected cyclosulfamidate 20. Global 
deprotection finally yielded the target compound 4. The 
synthesis of compounds 3, 5 and 9 (Figure 1B) and 
intermediates follows related strategies, as is described in the 
Supporting Information. 
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Scheme 1. Synthesis of α-D-galactose configured cyclosulfate 2 (A) and 
cyclosulfamidate 4 (B). Reagents and conditions: a) (i) SOCl2, Et3N, 
imidazole, DCM, 0 °C; (ii) RuCl3, NaIO4, CCl4, MeCN, 0 °C, 3 h, 12: 56 % 
and 20: 59 %; b) NH3, MeOH, rt, 3 h, 34 %; c) PtO2, H2, THF, rt, 4 h, 99 %; 
d) Boc2O, Et3N, DCM, rt, 16 h, 15: 93% and 19: 99 %; e) imidazole, MsCl, 
Et3N, CHCl3, rt, 16 h; f) DMF, 120 °C, 2 days, 47 % over 2 steps; g) 1 M 
NaOH, EtOH, 70 °C, 3 h, to rt, 16 h, 86 %; h) TFA, DCM, rt, 16 h, 71 %; i) 
Pd(OH)2, H2, MeOH, rt, 18 h, 57 %. 
 
α-D-Galactose configured cyclosulfate 2, cyclosulfamidates 3 
and 4, and cyclosulfamide 5 are predominantly in the 4C1 
conformation. 
Free energy landscapes (FELs) of inhibitors report the 
conformational behavior in solution well, and can therefore be 
used to predict the selectivity for GH active sites26. We 
calculated conformational FELs of compounds 2-5 using ab initio 
metadynamics (Figure 2A, S1 and S2). The FEL of α-gal-
cyclophellitol cyclosulfate 2 is strongly biased towards 4C1, with 
a secondary minimum around B2,5. This B2,5 conformer is 
unlikely to be enzyme active-site-reactive as it exhibits an 
equatorial C1-O bond (Figure S2). The 4C1 minimum of the 
substrate extends towards the TS-like 4H3 conformation, 
indicating that cyclosulfate 2 in a 4H3 conformation could be 
transiently populated on-enzyme, favoring the nucleophilic 
attack and formation of a glycosyl-enzyme adduct. The FELs of 
3-5 show that substitution of the cyclic sulfate trap by cyclic 
sulfamidates (3 and 4) or sulfamide (5) does not significantly 
affect the conformational preferences. The local B2,5 minimum 
in 4 is more pronounced, probably due to a hydrogen bond 
between the 2-OH and one cyclosulfamidate oxygen (Figure S2). 
 
Figure 2. Conformational free energy landscapes and crystal structures 
of α-gal-cyclosulfate 2 and α-gal-cyclosulfamidate 4 in α-gal A 
(agalsidase beta). A. α-Gal-cyclosulfate 2 and α-gal-cyclosulfamidate 4 
adopt 4C1 ground state conformations. The x and y axes of each graph 
correspond to the φ and θ Cremer-Pople puckering coordinates (in 
degrees), respectively. Isolines are 1 kcal/mol. B. α-Gal-cyclosulfate 2 
(left) reacts with the Asp170 nucleophile and adopts a 1S3 conformation 
covalent adduct (i.e., “intermediate-like”) in complex with agalsidase 
beta. Unreacted 4 (right) in complex with agalsidase beta adopts a 4C1 
“Michaelis-like” conformation in the active site. Electron density for 
protein side chains and ligands is REFMAC maximum-likelihood/σA-
weighted 2Fo − Fc contoured to 0.21 electrons/Å3 for 2 and 4. nuc = 
nucleophile; a/b = acid/base. 
 
α-D-Galactose configured cyclosulfate 2 and isosteres 4 and 5 
inhibit α-gal A in vitro. 
α-Gal-cyclosulfate 2, α-gal-cyclosulfamidates 3 and 4, α-gal-
cyclosulfamide 5, as well as the known α-galactosidase 
inhibitors α-gal-cyclophellitol 627, α-gal-cyclophellitol aziridine 
727, Gal-DNJ 828 and β-gal-cyclosulfate 9 were evaluated on 
their inhibitory potential against recombinant human GH27 α-
galactosidase A (α-gal A, Fabrazyme®, agalsidase beta) and their 
selectivity over human β-galactosidases, galactosidase beta 1 
(GLB1, GH35) and galactosylceramidase (GALC, GH59). We first 
determined apparent IC50 values by using fluorogenic 4-
methylumbelliferyl (4MU)-α- or -β-D-galactopyranose 
substrates (Table 1). α-Gal-cyclosulfate 2 effectively inhibits α-
gal A on a par with α-gal-cyclophellitol 6 (apparent IC50 = 25 vs 
13 μM, respectively), although less potently than α-gal-
cyclophellitol aziridine 7 (apparent IC50 = 40 nM). 
Cyclosulfamidate 4, with the sulfamidate nitrogen taking up the 
position occupied by the anomeric oxygen in the natural 
substrate, proved to be a rather good inhibitor (IC50 = 67 µM), 
whereas isomer 3 is inactive and sulfamide 5 considerably less 
potent (IC50 = 423 µM).  
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Table 1. Apparent IC50 values for in vitro inhibition of human recombinant α-galactosidase A (agalsidase beta), β-galactosidase GLB1 in human 
fibroblast lysates and GALC overexpressed in HEK293 cells. Inactivation rates and inhibition constants (kinact and KI) in human recombinant α-
galactosidase A (agalsidase beta); N.D., not determined; adue to weak inhibition; bdue to fast inhibition; N.A., not applicable. Reported values are 
mean ± standard deviation from 3 technical replicates. 
Compd. In vitro 
α-gal A 
(agalsidase beta) 
apparent 
IC50 (µM) 
In vitro 
β-gal 
(GLB1) 
apparent 
IC50 (µM) 
In vitro 
β-gal 
(GALC) 
apparent 
IC50 (µM) 
Kinetic 
Parameters 
α-gal A 
(agalsidase beta) 
kinact (min-1) and KI (µM) 
or Ki (µM) 
Kinetic 
Parameters 
α-gal A 
(agalsidase beta) 
kinact /KI (min-1µM-1) 
α-Gal-cyclosulfate 2 25 ± 2.5 >1000 >1000 Irreversible 
KI = 237 
kinact = 0.06 
0.25 
α-Gal-cyclosulfamidate 3 >1000 39 ± 4.6 95 ± 14 N.A. 
 
N.A. 
α-Gal-cyclosulfamidate 4 67 ± 4.7 >1000 >1000 Competitive 
Ki = 110 
- 
α-Gal-cyclosulfamide 5 423 ± 58 38 ± 1.7 191 ± 5.5 N.D.a 
 
N.D.a 
α-Gal-cyclophellitol 6 13 ± 0.95 0.84 ± 0.13 4.2 ± 0.51 Irreversible 
KI = 430 
kinact = 0.24 
0.55 
α-Gal-cyclophellitol 
azidiridine 7 
0.040 ± 0.005 0.93 ± 0.06 1.1 ± 0.30 Irreversible 
N.D.b 
16.4 
Gal-DNJ 8 0.079 ± 0.004 42 ± 0.72 433 ± 39 Competitive 
Ki = 0.23 
- 
β-Gal-cyclosulfate 9 >1000 >1000 >1000 N.A. N.A. 
 
We also measured the apparent IC50 values for inhibition against 
two human β-galactosidases: GLB1 (measured in human 
fibroblast lysates) and GALC (measured in overexpressing 
HEK293 cell medium). Cyclosulfate 2 and cyclosulfamidate 4 
appear to be more selective than cyclophellitol epoxide 6 and 
aziridine 7, and we reason this to be due to the 4C1 conformation 
adopted by 2 and 4, which corresponds to the Michaelis 
complex conformation in α-galactosidases, but not in β-
galactosidases (compound 2 is inactive up to 1 mM whereas 6 
and 7 display low micromolar activity towards GLB1 and GALC). 
β-Gal-cyclosulfate 9, which in principle neither mimics the 
Michaelis complex nor the transition state conformation of β-
galactosidases29,30, is inactive against β- and α-galactosidases up 
to 1 mM. Cyclosulfamidate 4 and Gal-DNJ 8 show selectivity 
over α-glucosidase GAA, whereas both inhibit human 
recombinant β-glucosidase (GBA) (Table S1). 
We next explored the reversibility of inhibition by our new cyclic 
sulfate analogues. Enzymes were pre-incubated for different 
time periods (30, 60, 120, 240 min) with inhibitors at 
concentrations of their corresponding apparent IC50 values, 
after which residual α-gal A activity was determined (Figure S3). 
Whilst cyclosulfate 2 is an irreversible inhibitor (a decrease in a-
galactosidase activity with longer incubation time), 
cyclosulfamidate 4 and cyclosulfamide 5 were reversible 
inhibitors as revealed by a constant residual activity with 
extended incubation times. This was confirmed by kinetic 
studies monitoring the absorbance generated by the hydrolysis 
of 2,4-dinitrophenyl-α-D-galactopyranoside substrate (2,4-DNP-
α-gal) (Table 1). The irreversible inhibitors 2, 6 and 7 follow 
pseudo-first order kinetics. Although α-cyclosulfate 2 has a 
similar kinact/KI ratio as α-cyclophellitol 6 (kinact/KI = 0.25 vs 0.55 
min-1mM-1, respectively), it has a stronger initial binding 
constant (KI) and a slower inactivation rate constant (kinact) (2: KI 
= 237 μM and kinact = 0.06 min-1; 6: KI = 430 μM and kinact = 0.24 
min-1). Only a kinact/KI ratio could be measured for α-aziridine 7 
due to fast inhibition (kinact/KI = 16.4 min-1mM-1). Kinetics with 
increasing 2,4-DNP-α-gal concentrations showed that 
cyclosulfamidate 4 reversibly inhibits α-galactosidase with a Ki 
of 110 μM. 
 
Structural analysis of α-gal-cyclosulfate 2 and α-gal-
cyclosulfamidate 4 in complex with agalsidase beta. 
Firstly, in order to confirm the covalent inhibition by the cyclic 
sulfate, the X-ray structure of agalsidase beta in complex with 2 
(PDB:6IBM) was determined to 1.99 Å, revealing a single 
molecule of 2 covalently bound to the enzyme active site (Figure 
2B). The observed electron density unambiguously shows that 
α-cyclosulfate 2 has reacted by attack of the catalytic 
nucleophile, Asp 170, to form a covalent enzyme-inhibitor 
complex. This covalent complex adopts a 1S3 conformation, 
consistent with the conformation of the covalent intermediate 
in the α-galactosidase reaction itinerary (Figure 1A). Upon 
nucleophilic attack to the cyclic sulfate, the sulfate forms 
hydrogen bonds with Asp231 and Cys172, the latter suffering a 
shift in position.  
Armed with the knowledge that 2 indeed forms a covalent 
adduct to agalsidase beta, we moved onto ascertain if the 
cyclosulfamidate 4 would, as envisaged, function as a non- 
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Figure 3. Effect of α-cyclosulfamidate 4 and Gal-DNJ 8 on thermal stability and cell culture medium stability of agalsidase. A. Heat-induced melting 
profiles of lysosomal α-gal A recorded by thermal shift, measured at pH 4.5, 5.5 and 7.4 in the presence of α-cyclosulfamidate 4 and Gal-DNJ 8. 
Melting points (Tm) were determined through thermal shift analyses by monitoring the florescence of Sypro Orange dye (λem 585 nm) as a function 
of temperature (see supplementary information). B. Schematic representation of stabilization effect assay. Agalsidase beta was incubated with 
inhibitor for 15 min in DMEM/F-12 medium and subsequently incubated with ConA sepharose beads for 1 h at 4 °C and washed to remove inhibitor. 
Residual α-Gal activity was quantified with 4-MU-α-gal substrate. C. Percentage of α-gal A residual activity after 15 min incubation in DMEM/F-12 
medium in the presence of inhibitor α-gal-cyclosulfamidate 4 (at 0, 100, 200, 500 µM) and Gal-DNJ 8 (0, 1, 10 and 50 µM), followed by post final 
ConA purification. Percentages are calculated considering the 100 % activity of α-gal A obtained at 0 min incubation time (n=2, error bars indicate 
mean ± standard deviation). 
 
covalent, active-centre-directed, inhibitor of the enzyme-
replacement enzyme. In contrast to cyclosulfate 2, 
cyclosulfamidate 4 (PDB: 6IBK determined to 2.07 Å) was indeed 
shown to reversibly bind the catalytic site (Figure 2B). As 
expected, the α-galactose configured cyclosulfamidate 4 adopts 
a 4C1 “Michaelis-like” complex conformation in the active site. 
Interestingly, the NH from the cyclosulfamidate moiety forms a 
hydrogen bond with the acid/base Asp231. 
Thermostability of agalsidase beta in the presence of α-
cyclosulfamidate 4 and Gal-DNJ 8. 
Competitive α-galactosidase inhibitors, including Gal-DNJ 8, are 
currently investigated in clinical studies as stabilizers of 
recombinant enzyme, where they are deployed to enhance 
enzyme replacement efficacy. In such a treatment regime, 
enzyme and active site inhibitor are administered jointly11,14,16. 
The stability of a recombinant enzyme relative to the 
temperature is considered to reflect well its stability in body 
circulation31, and can be measured with ease, also in the 
presence of competitive inhibitors designed to stabilize protein 
fold31,32. Accordingly, we performed thermal stability assays 
(TSAs) on agalsidase beta alone and in the presence of 
increasing concentrations of 2, 4 or 8. 
Thermal melting profiles of lysosomal α-gal A revealed that α-
gal A is most thermostable at pH 5.5 (Figure 3A and S4), which 
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is consistent with α-gal A being a lysosomal enzyme. α-Gal-
cyclosulfamidate 4 stabilizes α-gal A at pH 7.4 with a ΔTmmax of 
17.4 °C, compared to a ΔTmmax of 34.3 °C produced by Gal-DNJ 
8 (Figure 3A and S4). TSA effects at acidic pHs were lower for 
both 4 and Gal-DNJ 8, with recorded ΔTmmax values of 9.3 °C and 
22.3 °C for 4 and Gal-DNJ 8, respectively at pH 5.5, and ΔTmmax 
values of 9.7 °C and 21.2 °C for the same compounds at pH 4.5. 
Surprisingly, we observed no thermostabilization effect on α-gal 
A in the presence of α-gal-cyclosulfate 2, despite this compound 
being an irreversible α-galactosidase inhibitor. Possibly, the 
sulfate group does not provide the optimal enzyme-ligand 
interactions to induce stabilization of α-galactosidase when the 
ring is in 1S3 conformation adopted by covalently bound 2, 
compared to the 4C1 conformations adopted by both 4 and Gal-
DNJ 8. 
Stabilization of agalsidase beta by α-cyclosulfamidate 4 in cell 
culture medium. 
Agalsidase beta shows poor stability in plasma at pH of 7.3 - 7.4, 
with only ~25 % of the hydrolytic activity being retained after 
incubation of enzyme at 1 µg/mL in human plasma for 30 
minutes33. Given the stabilizing effect observed for 4 in the 
above described TSAs, we investigated the ability of this 
compound to stabilize agalsidase beta in culture medium at 
physiological pH compared to Gal-DNJ 834.We first investigated 
the stabilization effect of the inhibitors in culture medium 
alone, as surrogate measure for plasma stability (Figure 3B and 
3C). Incubation of agalsidase beta (25 µL of 2.5 µg/µL) in cell 
culture medium (Dulbecco's Modified Eagles Medium/Nutrient 
Mixture F-12 (DMEM/F12), supplemented with 10 % fetal calf 
serum and 1 % penicillin/streptomycin) led to 80 % loss of 
activity within 15 min, in line with the poor stability of this 
enzyme in blood plasma. To assess the stabilizing effects of 2, 4 
and Gal-DNJ 8 in cell culture media, agalsidase beta was 
incubated with increasing concentrations of these compounds, 
followed by capture of the enzyme on concanavalin A (ConA) 
sepharose beads, washing to remove bound inhibitor, and 
quantification of residual α-galactosidase activity with 4MU-α-
gal substrate. Media stabilization of agalsidase beta followed 
the same trend as observed in TSAs, with 2 failing to stabilize 
the enzyme and instead irreversibly inhibiting agalsidase beta. 
In contrast, α-gal-cyclosulfamidate 4 and Gal-DNJ 8 both 
prevented inactivation of agalsidase beta in cell culture media 
(pH 7.2) - ~75 % residual α-gal-A activity was retained after 
incubation with 4 (at 500 µM) or Gal-DNJ 8 (at 50 µM) (Figure 
3C). 
Competitive activity-based protein profile (ABPP) on 
recombinant α-galactosidases. 
We studied the binding of α-cyclosulfamidate 4 and Gal-DNJ 8 
to the commercial α-galactosidases: agalsidase beta 
(Fabrazyme®), agalsidase alpha (Replagal®) and α-galactosidase 
B (N-acetylgalactosaminidase, NAGA) by competitive activity-
based protein profiling (ABPP, Figure 4). Enzymes were 
incubated with increasing concentrations (ranging from 0 to 
1000 µM) of both α-cyclosulfamidate 4 and Gal-DNJ 8 for 30 min 
at 37 °C, followed by incubation with 0.2 µM of an α-
galactosidase Cy5 activity-based probe (ABP 10, Figure S5) for 
30 min at 37 °C. After incubation the samples were analyzed by  
 
Figure 4. Competitive ABPP in α-galactosidases. α-Galactosidases 
(agalsidase beta 200 ng and agalsidase alpha 200 ng) and α-N-
acetylgalactosaminidase (NAGA, 200 ng) were pre-incubated with α-
cyclosulfamidate 4 (0-1000 µM) or Gal-DNJ 8 (0-1000 µM) for 30 min 
followed by fluorescent labelling with Cy5 α-galactosidase ABP 10. ABP: 
activity-based probe, CBB: coomassie brilliant blue staining. 
 
sodium dodecyl sulfate-polyacrylamide gels (SDS- PAGE), 
followed by fluorescent scan of the gels as previously 
described27,33. Competitive ABPP revealed that α-
cyclosulfamidate 4 (100-500 µM) and Gal-DNJ 8 (1-10 µM) 
inhibit both recombinant human α-galactosidases and N-
acetylgalactosaminidase. 
In situ treatment of cultured fibroblasts from patients with 
Fabry disease. 
We next investigated whether the stabilizing effect of α-
cyclosulfamidate 4 towards agalsidase beta produced an 
improvement in the cellular uptake of the enzyme by 
fibroblasts. We performed in situ studies in 5 different primary 
cell lines obtained from adult male volunteers: wild-type (WT, 
Control) representing normal α-gal A activity, 2 classic Fabry 
mutant fibroblasts (R301X and D136Y) with no α-gal A activity 
and 2 atypical variant Fabry mutants (A143T and R112H) with 
substantially lowered residual α-gal A activity. Fibroblasts were 
incubated with 0.5 % DMSO (untreated) or either 4 (200 µM) or 
Gal-DNJ 8 (20 µM) (in blue), agalsidase beta (100 ng) or with a 
combination of both enzyme and stabilizing agent (in green) 
(Figure 5A). After 24 h treatment, the cells were harvested and 
homogenized, and the intracellular α-gal A activity of the 
corresponding cell lysates was measured. WT cell line presented 
normal α-gal A activity whereas untreated classic Fabry patients 
(R301X and D136Y) and variant mutation samples (A143T and 
R112H) showed reduced enzymatic activity. None of the cell 
lines, not even classical Fabry fibroblasts R301X and D136Y, 
showed significant increase in α-gal A activity when incubated 
with 4 (200 µM) or 8 (20 µM) alone for 24 h. Of note, Gal-DNJ 8 
is known to enhance α-gal A activity in R301Q lymphoblasts 
after in situ 4-day treatment of a 100 µM daily dose.34 
Treatment with agalsidase beta showed a considerable increase 
in α-gal A activity in all the studied cell lines. This effect was 
improved in
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Figure 5. Effect on α-gal A activity in fibroblasts culture and medium following treatment with α-cyclosulfamidate 4 and Gal-DNJ 8. A. Fibroblasts of WT, classic 
Fabry (R301X and D136Y) and variant Fabry (A143T and R112H) were untreated or incubated with α-cyclosulfamidate 4 (200 µM), Gal-DNJ 8 (20 µM), agalsidase 
beta (200 ng/mL) or a combination of enzyme and stabilizing agent for 24 h. Then, the medium was collected, cells were harvested, and α-gal A activity was 
measured in the cell homogenates by 4-MU-α-gal assay. In all cell lines co-administration of α-cyclosulfamidate 4 or Gal-DNJ 8 with agalsidase beta increased 
intracellular α-gal A activity when compared to cells treated with only agalsidase beta. B. α-Gal A activity in cell culture medium samples was measured after 
ConA purification. α-Gal A activity is at least two times higher in all the cell lines treated with α-cyclosulfamidate 4 (200 µM) or Gal-DNJ 8 (20 µM). Reported 
activities are mean ± standard deviation from two biological replicates, each with two technical replicates, * p < 0.5; **, p < 0.01; ***, p < 0.001. 
 
 
Figure 6. Gb3 and Lyso-Gb3 quantification in cultured fibroblasts treated with 
agalsidase beta co-administrated with α-cyclosulfamidate 4 and Gal-DNJ 8. 
Gb3 (A) and lysoGb3 (B) levels (pmol/mL of sample) measured by LC-MS/MS 
in Fabry fibroblasts from WT and classic Fabry patients (R301X and D136Y) 
treated with agalsidase beta (200 ng/mL) with or without α-cyclosulfamidate 
4 (200 µM) and Gal-DNJ 8 (20 µM) for 24 h. Reported activities are mean ± 
standard deviation from two biological replicates, each with two technical 
replicates, * p < 0.5; **, p < 0.01 
 
 
 
most cases with the combinatorial treatment of agalsidase beta and 
4 or 8 after 24 h incubation. We also measured α-gal A activity in 
media in order to confirm that the increase in α-gal A activity in cell 
lysates is due to stabilization of the enzyme (Figure 5B). Thus, culture 
media were collected before harvesting the cells and α-gal A activity 
was measured after ConA purification. α-Gal A activity in media was 
at least double in all the cell lines treated with α-cyclosulfamidate 4 
(200 µM) or Gal-DNJ 8 (20 µM), consisting with these compounds 
preventing α-gal A degradation during cell culture. 
Gb3 and LysoGb3 levels are corrected by α-cyclosulfamidate 4. 
Generally, Fabry patients present elevated Gb3 which is further 
metabolized by acid ceramidase into LysoGb3 in lysosomes35. 
LysoGb3 constitutes a signature of Fabry disease and allows 
diagnostic monitoring of disease progression2,3,36–38, and has been 
linked to neuronopathic pain and renal failure through its effect on 
nociceptive neurons and podocytes39–42. We investigated whether 
co-administration of α-cyclosulfamidate 4 and Gal-DNJ 8 with 
agalsidase beta would also have a positive effect in correcting these 
toxic metabolite levels. Gb3 and lysoGb3 levels from in situ treated 
cells were measured by LC-MS/MS (Figure 6). Normal Gb3 and 
lysoGb3 levels observed in wild-type cells range around 2000 
pmol/mL and 2 pmol/mL of Gb3 and lysoGb3, respectively. Cultured 
fibroblasts from classic Fabry patients (R301X and D136Y) treated 
with agalsidase beta resulted in a reduction of Gb3 and lysoGb3. This 
reduction was similar when fibroblasts were treated with the 
combination of α-cyclosulfamidate 4 (200 µM) or Gal-DNJ 8 (20 µM) 
and agalsidase beta. Variant Fabry A143T cell line presents normal 
Gb3 and lysoGb3 basal levels, whereas in R112H fibroblasts, these 
metabolites are increased and not corrected by agalsidase beta itself 
or inhibitor-agalsidase beta combination treatment (Figure S6). 
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Figure 7. Effect on α-gal A activity and Lyso-Gb3 correction in cultured fibroblasts treated with α-cyclosulfamidate 4 and Gal-DNJ 8. Fibroblasts of WT and 
classic Fabry (R301X) were incubated with agalsidase beta (200 ng/mL) or the combination of enzyme (200 ng/mL or 100 ng/mL) and stabilizing agent (4 200 
µM or 8 20 µM) for 4 days. Then, the medium was collected, cells were harvested, and α-gal A activity was measured in the cell homogenates by 4-MU-α-gal 
assay. A. Intracellular α-gal A activity in fibroblasts treated with agalsidase beta (200 ng/mL) or the combination of α-cyclosulfamidate 4 (200 µM) or Gal-DNJ 
8 (20 µM) with agalsidase beta (200 ng/mL) for 4 days. B. LysoGb3 levels measured by LC-MS/MS in Fabry fibroblasts from panel A. C. Intracellular α-gal A 
activity is comparable in cell lines treated with the combination of α-cyclosulfamidate 4 (200 µM) or Gal-DNJ 8 (20 µM) but this requires only half the 
concentration of agalsidase beta (100 ng/mL). D. Intracellular α-gal A activity per ng of agalsidase beta in fibroblasts treated with agalsidase beta (100 ng/mL) 
or the combination of α-cyclosulfamidate 4 (200 µM) or Gal-DNJ 8 (20 µM) with half concentration of agalsidase beta (100 ng/mL). E. LysoGb3 levels measured 
by LC-MS/MS in Fabry fibroblasts from panel C or D. Reported lipid levels are mean ± standard deviation from two biological replicates, each with two technical 
replicates, * p < 0.5; **, p < 0.01; ***, p < 0.001. 
In situ 4-day treatment of cultured fibroblasts: increased α-gal A 
activity and Gb3 metabolites correction by α-cyclosulfamidate 4. 
We next investigated whether the beneficial effect could be 
potentiated by extended incubation treatments. Thus, WT and 
classic Fabry (R301X) fibroblasts were treated with agalsidase beta 
(200 ng/mL) or with a combination of enzyme (200 ng/mL) and α-
cyclosulfamidate 4 (200 µM) or Gal-DNJ 8 (20 µM) for 4 days. 
Fibroblasts were treated every 24 h with new medium and/or 
enzyme with or without inhibitor, and medium samples were 
collected for α-gal A activity quantification (See supporting 
information, Figure S7). α-Gal A activity was 3-4 times higher in 
fibroblasts treated with the combination of recombinant α-gal A and 
α-cyclosulfamidate 4 (200 µM) or Gal-DNJ 8 (20 µM) than those 
treated with agalsidase beta alone (Figure 7A). This increase in α-gal 
A activity correlates with the reduction of Lyso-Gb3 from ~14 
pmol/mL to ~4 pmol/mL in the cell lysates of Fabry (classic R301X) 
fibroblasts (Figure 7B). We finally studied whether the amount of 
required ERT could be decreased when stabilized with 4 or Gal-DNJ 8 
and still produce a similar effect. WT and Fabry (classic R301X) 
fibroblasts were treated with agalsidase beta at 200 ng/mL and 100 
ng/mL. A reduction in toxic metabolites can be achieved in 4 days 
with half the concentration of enzyme (100 ng/mL) when either α-
cyclosulfamidate 4 (200 µM) or Gal-DNJ (20 µM) is added (Figure 
7C,D), with a similar reduction of toxic Lyso-Gb3 from ~10 pmol/mL 
to ~5-6 pmol/mL in the cell lysates of Fabry (classic R301X) fibroblasts 
(Figure 7E). 
 
 
Discussion 
ERT with intravenous administration of recombinant human α-D-
galactosidase (agalsidase beta, Fabrazyme® or agalsidase alpha, 
Replagal®) reduces the levels of Gb3 and lyso-Gb3 in some tissues of 
Fabry patients, but its clinical efficacy is still limited5–7,43. The limited 
enzyme stability in plasma is a major drawback, and it is for this 
reason that enzyme active site binders that stabilize recombinant 
enzyme in circulation are pursued – with Gal-DNJ 8 (Migalastat®) 
currently in use in the clinic as the benchmark. Here we report the 
design and synthesis of the first-in-class conformational glycosidase 
inhibitor and α-gal A stabilizing agent, α-cyclosulfamidate 4. We 
show that this compound reversibly and selectively inhibits 
agalsidase beta with an IC50 value of 67 µM and a Ki of 110 µM. Ab 
initio metadynamics calculations and structural analysis of α-
cyclosulfamidate 4 in complex with agalsidase beta show that this 
inhibitor binds in a 4C1 conformation mimicking the Michaelis 
complex conformation. We demonstrate that α-cyclosulfamidate 4 
stabilizes recombinant human α-D-galactosidase (agalsidase beta, 
Fabrazyme®) in thermal stabilization assays and show that this 
prevents its degradation in cell culture medium. We further show 
that both α-gal-cyclosulfamidate 4 and Gal-DNJ 8 stabilize the 
enzyme more significantly at neutral pH than under acidic conditions 
(ΔTmmax difference of 8.1 °C for 4 and ΔTmmax difference of 12.2 °C 
for Gal-DNJ 8).  
To further study the stabilizing effect, we investigated whether α-
gal-cyclosulfamidate 4 and Gal-DNJ 8 would stabilize α-gal A activity 
in situ cell conditions. Treatment of fibroblasts (WT, classic and 
variant Fabry cell lines) with only α-gal-cyclosulfamidate 4 (at 200 
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µM) and Gal-DNJ 8 (at 20 µM) for 24 h shows no effect on α-D-
galactosidase activity. However, we observe an increased α-D-
galactosidase activity in all cells treated with the combination of 
agalsidase beta and stabilizing agents (4 at 200 µM and 8 at 20 µM) 
when compared to the cells treated only with agalsidase beta. This 
result also correlates with an increased α-D-galactosidase activity in 
the cell medium of the cells treated with enzyme and 4 or 8. The 
stabilizing effect is more pronounced when cells are treated for 
longer time (4 days), suggesting that the agalsidase beta complexed 
with α-gal-cyclosulfamidate 4 or Gal-DNJ 8 is stabilized in the cell 
medium, internalized and dissociated from the reversible inhibitor in 
the lysosomes. Finally, co-administration of α-cyclosulfamidate 4 or 
Gal-DNJ 8 with agalsidase beta highlights a similar correction of toxic 
Gb3 and lyso-Gb3 metabolite levels as with the ERT alone. 
Importantly, similar α-gal A activity and correction of toxic 
metabolites is achieved with half the concentration of agalsidase 
beta when this is stabilized by α-cyclosulfamidate 4 or Gal-DNJ 8. The 
synergy between Gal-DNJ 8 and the human recombinant α-gal A in 
cultured fibroblasts from Fabry patients has recently been 
demonstrated both in agalsidase alpha and beta16,19. This synergism, 
together with our agalsidase beta stabilization results, supports the 
idea that the efficacy of a combination treatment may be superior to 
ERT or PC alone for several reasons. Co-administration of ERT and 
active site inhibitor may be effective in all Fabry patients, 
independent of mutations in their endogenous α-gal A. Furthermore, 
stabilization of the recombinant human α-gal A by a stabilizing agent 
may reduce the required enzyme dosages or extend IV injections 
intervals, and therefore improve patient’s life-style and reduce side 
effects and treatment costs. 
Conclusions 
In conclusion, we have developed a new class of α-D-galactosidase 
inhibitors based on cyclophellitol cyclosulfamidate as a 
conformational Michaelis complex isostere. Although 
cyclosulfamidate 4 is a 1000-fold weaker inhibitor of recombinant α-
gal A compared to Gal-DNJ 8 in vitro, it stabilizes α-gal A in cellulo at 
only 10 fold higher concentration, and we argue that non-basic, 
competitive glycosidase inhibitors are attractive starting points for 
clinical development as stabilizers of (recombinant) glycosidases in 
the context of lysosomal storage disorders. As well, compound 4 and 
its structural isosteres (3 and 5) comprise a new class of competitive 
glycosidase inhibitors that stabilize agalsidase beta for the first time, 
not by the glycoside configurational mimicry and basic nature that is 
the hallmark of iminosugars (including Migalastat®), but by 
configurational and conformational mimicry of the Michaelis 
complex. Michaelis complex or product-like conformational 
competitive inhibitors have been reported that act on other 
glycosidases, for instance, thio-oligosacharides44–46 and 
kifunensine47,48. We believe that transferring the structural 
characteristics of our cyclosulfamidates to differently configured 
structural analogues may yield potent and selective competitive 
inhibitors targeting other glycosidases and that these may have 
biological or biomedical value in their own right, be it as stabilizing 
agents or as classical enzyme inhibitors. 
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